3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Lymphoid
1
Conditions
Multiple Myeloma
424
Neoplasms, Plasma Cell
68
Lymphoma, Mantle-Cell
66
Lymphoma
65
Recurrence
63
Lymphoma, Non-Hodgkin
43
Lymphoma, Follicular
42
Precursor Cell Lymphoblastic Leukemia-Lymphoma
41
Leukemia, Myeloid, Acute
36
Lymphoma, Large B-Cell, Diffuse
34
Waldenstrom Macroglobulinemia
33
Lymphoma, B-Cell, Marginal Zone
30
Leukemia, Lymphocytic, Chronic, B-Cell
28
Neoplasms
24
Carcinoma, Non-Small-Cell Lung
24
Immunoglobulin Light-chain Amyloidosis
23
Leukemia
21
Hodgkin Disease
17
Lymphoma, B-Cell
14
Burkitt Lymphoma
14
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
13
Myelodysplastic Syndromes
13
Lymphoma, Large-Cell, Anaplastic
13
Hematologic Neoplasms
13
Immunoblastic Lymphadenopathy
12
Breast Neoplasms
12
Mycosis Fungoides
11
Lymphoma, T-Cell, Cutaneous
11
Lymphoma, Large-Cell, Immunoblastic
11
Congenital Abnormalities
11
Interventions
Etoposide
6
Vincristine
5
Prednisone
5
Doxorubicin
5
Cyclophosphamide
5
Rituximab
4
prednylidene
3
deltacortene
3
daratumumab
2
Cytarabine
2
varlilumab
1
pomalidomide
1
merphos
1
ixazomib
1
carmustine, poliferprosan 20 drug combination
1
belantamab mafodotin
1
Vorinostat
1
Specimen Handling
1
Peripheral Blood Stem Cell Transplantation
1
Nivolumab
1
Methotrexate
1
Melphalan
1
Magnetic Resonance Spectroscopy
1
Immunoglobulin G
1
Hydrocortisone
1
Disulfides
1
Dexamethasone
1
Carmustine
1
CT-P10
1
Bortezomib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Interventional
×
Plasmablastic Lymphoma
×
Bortezomib
×
Clear all
NCT04915248
2025-12-24
FIL_DALYA
Fondazione Italiana Linfomi - ETS
Phase 2
Recruiting
28 enrolled